secwatch.observer — SEC 8-K summary
======================================

Issuer:     Altimmune, Inc. (ALT)
CIK:        0001326190
Form:       8-K
Filed at:   2026-04-24T23:59:59+00:00
Accession:  0001104659-26-048552
Event type: other_material
Sentiment:  neutral
Materiality: 0.60
Item codes: 1.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Altimmune raises ~$211M in public offering to fund MASH Phase 3 trial
---------------------------------------------------------------------

- Offered 64.25M common shares at $3.00/share and pre-funded warrants for up to 10.75M shares.
- Net proceeds of ~$211.2M after underwriting discounts and expenses; offering closed April 24, 2026.
- Proceeds to fund pemvidutide Phase 3 MASH trial and pre-commercial activities.
- Common stock warrants exercisable at $3.00/share for 5 years or 45 days after Phase 3 data announcement.
- Warrants not listed on Nasdaq; beneficial ownership limits of 4.99% or 9.99% apply.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1326190/000110465926048552/0001104659-26-048552-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1326190/000110465926048552/tm2612493d2_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-26-048552

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer